The Biorepository for Scripps Health
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/4/2017 |
| Start Date: | November 2009 |
| End Date: | January 2020 |
The investigators propose to establish a Biorepository of both diseased and normal tissue
collected from subjects undergoing surgery for solid tumor resection. In cooperation with
the Scripps Cancer registry, the investigators will also establish an anonymized database of
corresponding clinical information including response to treatment, disease status, and
recurrence.
The Biorepository for Scripps Health will be able to process, preserve, and distribute
samples to scientific and medical researchers at Scripps.
collected from subjects undergoing surgery for solid tumor resection. In cooperation with
the Scripps Cancer registry, the investigators will also establish an anonymized database of
corresponding clinical information including response to treatment, disease status, and
recurrence.
The Biorepository for Scripps Health will be able to process, preserve, and distribute
samples to scientific and medical researchers at Scripps.
Biorepository samples will be utilized in a variety of research studies intended to help in
the diagnosis and/or treatment of patients, including the possible identification of
therapeutic targets or genetic identifiers of cancers and possibly other diseases. Various
technologies including gene expression, genotyping, DNA and RNA sequencing, protein and
metabolite analysis may be used in the course of the various studies An exemplary project
currently under consideration is one in which Scripps Genomic Medicine is comparing the DNA
sequence of both a patient's tumor and their germline DNA to identify genetic differences
between the two. These differences could help identify specific pathways that are regulating
the tumor and disease thus leading to potentially valuable information in how to treat that
individual patient as well as other patients with similar genetic characteristics. In
addition, differences between the tumor and germ-line observed in multiple patients could
help identify therapeutic targets that are cancer specific. A secondary exemplary project
which is currently underway is one in which Scripps Genomic Medicine is undertaking RNA
sequencing to identify "fusion genes" which are hybrid genes formed from two previously
separate genes and are a type of genetic mutation that has been identified in certain types
of cancers including those of the prostate and breast and certain forms of leukemia.
Identifying new fusion genes could provide valuable insights into both treatment protocols
and new therapeutic targets.
The goal of this project is to expand and improve the bio-repository already established
within the Scripps Genomic Medicine (SGM) group. Presently, the collection has been focused
on the collection of predominately prostate tumors and blood as the corresponding normal
tissue. The current collection is annotated with pathology information and limited medical
information collected from the patient during the consenting process; no post surgical
information is collected. We believe that collection can be enhanced by (i) modifying the
tumor collection process, (ii) simplifying the means of consenting the patients such that it
relies upon the general surgical consent and (iii) using de-identified medical data already
consolidated in the Cancer registry as a means of annotating the tissue samples.
the diagnosis and/or treatment of patients, including the possible identification of
therapeutic targets or genetic identifiers of cancers and possibly other diseases. Various
technologies including gene expression, genotyping, DNA and RNA sequencing, protein and
metabolite analysis may be used in the course of the various studies An exemplary project
currently under consideration is one in which Scripps Genomic Medicine is comparing the DNA
sequence of both a patient's tumor and their germline DNA to identify genetic differences
between the two. These differences could help identify specific pathways that are regulating
the tumor and disease thus leading to potentially valuable information in how to treat that
individual patient as well as other patients with similar genetic characteristics. In
addition, differences between the tumor and germ-line observed in multiple patients could
help identify therapeutic targets that are cancer specific. A secondary exemplary project
which is currently underway is one in which Scripps Genomic Medicine is undertaking RNA
sequencing to identify "fusion genes" which are hybrid genes formed from two previously
separate genes and are a type of genetic mutation that has been identified in certain types
of cancers including those of the prostate and breast and certain forms of leukemia.
Identifying new fusion genes could provide valuable insights into both treatment protocols
and new therapeutic targets.
The goal of this project is to expand and improve the bio-repository already established
within the Scripps Genomic Medicine (SGM) group. Presently, the collection has been focused
on the collection of predominately prostate tumors and blood as the corresponding normal
tissue. The current collection is annotated with pathology information and limited medical
information collected from the patient during the consenting process; no post surgical
information is collected. We believe that collection can be enhanced by (i) modifying the
tumor collection process, (ii) simplifying the means of consenting the patients such that it
relies upon the general surgical consent and (iii) using de-identified medical data already
consolidated in the Cancer registry as a means of annotating the tissue samples.
Inclusion Criteria:
- Age 18 or older
- Undergoing surgical resection of solid tumor
- Completion of general surgical consent (authorizing "pathologist to use his or her
discretion in the disposition or use of any tissues removed during surgery or other
procedure unless otherwise directed by my physician. I understand that tissues that
are removed may be used for teaching purposes as well as research, institutional or
commercial".)
Exclusion Criteria:
- Does not meet all of the inclusion criteria above.
We found this trial at
1
site
Click here to add this to my saved trials
